Alexis A. Morrell

Alexis A. Morrell

Auto-generated profile, based on publicly available information

Alexis A. Morrell

University of Miami, Miami, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in World Neurosurgery
Verified
Journal Article
Closed access
VGVaidya Govindarajan
Vaidya Govindarajan
ELEvan M. Luther
Evan M. Luther
AMAlexis A. Morell
Alexis A. Morell
JBJoshua D. Burks
Joshua D. Burks
HKHunter King
Hunter King
Michael E. IvanMichael E. Ivan
Michael E. Ivan

18 March 2022 in World Neurosurgery
Verified
Journal Article
Closed access
VGVaidya Govindarajan
Vaidya Govindarajan
Ashish H. ShahAshish H. Shah
Ashish H. Shah
LDLong Di
Long Di
SRSarah Rivas
Sarah Rivas
RSRobert K Suter
Robert K Suter
MFMacarena De La Fuente
Macarena De La Fuente

19 September 2022 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
AMAlexis A Morell
Alexis A Morell
DEDaniel G Eichberg
Daniel G Eichberg
ASAshish H Shah
Ashish H Shah
ELEvan Luther
Evan Luther
VLVictor M Lu
Victor M Lu
MIMichael E Ivan
Michael E Ivan
Large-scale brain networks and higher cognitive functions are frequently altered in neuro-oncology patients, but comprehensive non-invasive brain mapping is difficult to achieve in the clinical setting. The objective of our study is to evaluate traditional and non-traditional eloquent areas in brain tumor patients using a machine-learning platform. We retrospectively included patients who underwent surgery for brain tumor resection at our Institution. Preoperative MRI with T1-weighted and DTI sequences were uploaded into the Quicktome platform. We categorized the integrity of nine large-scale brain networks: language, sensorimotor, visual, ventral attention, central executive, default mode, dorsal attention, salience and limbic. Network integrity was correlated with preoperative clinical data. One-hundred patients were included in the study. The most affected network was the central executive network (49%), followed by the default mode network (43%) and dorsal attention network (32%). Patients with preoperative deficits showed a significantly higher number of altered networks before the surgery (3.42 vs 2.19, P < .001), compared to patients without deficits. Furthermore, we found that patients without neurologic deficits had an average 2.19 networks affected and 1.51 networks at-risk, with most of them being related to non-traditional eloquent areas (P < .001). Our results show that large-scale brain networks are frequently affected in patients with brain tumors, even when presenting without evident neurologic deficits. In our study, the most commonly affected brain networks were related to non-traditional eloquent areas. Integrating non-invasive brain mapping machine-learning techniques into the clinical setting may help elucidate how to preserve higher-order cognitive functions associated with those networks.

19 January 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JRJared C. Reese
Jared C. Reese
HFHassan A. Fadel
Hassan A. Fadel
JPJacob Pawloski
Jacob Pawloski
MSMariam Samir
Mariam Samir
SHSameah Haider
Sameah Haider
ILIan Lee
Ian Lee
Purpose Laser interstitial thermal therapy (LITT) is a minimally invasive cytoreductive treatment option for brain tumors with a risk of vascular injury from catheter placement or thermal energy. This may be of concern with deep-seated tumors that have surrounding end-artery perforators and critical microvasculature. The purpose of this study was to assess the risk of distal ischemia following LITT for deep-seated perivascular brain tumors. Methods A retrospective review of a multi-institution database was used to identify patients who underwent LITT between 2013 and 2022 for tumors located within the insula, thalamus, basal ganglia, and anterior perforated substance. Demographic, clinical and volumetric tumor characteristics were collected. The primary outcome was radiographic evidence of distal ischemia on post-ablation magnetic resonance imaging (MRI). Results 61 LITT ablations for deep-seated perivascular brain tumors were performed. Of the tumors treated, 24 (39%) were low-grade gliomas, 32 (52%) were high-grade gliomas, and 5 (8%) were metastatic. The principal location included 31 (51%) insular, 14 (23%) thalamic, 13 (21%) basal ganglia, and 3 (5%) anterior perforated substance tumors. The average tumor size was 19.6 cm3 with a mean ablation volume of 11.1 cm3. The median extent of ablation was 92% (IQR 30%, 100%). Two patients developed symptomatic intracerebral hemorrhage after LITT. No patient had radiographic evidence of distal ischemia on post-operative diffusion weighted imaging. Conclusion We demonstrate that LITT for deep-seated perivascular brain tumors has minimal ischemic risks and is a feasible cytoreductive treatment option for otherwise difficult to access intracranial tumors.

19 July 2021 in Surgical Neurology International
Verified
Journal Article
Open access
KKKhadeja Khan
Khadeja Khan
ELEvan Luther
Evan Luther
AMAlexis A. Morrell
Alexis A. Morrell
STSze Kiat Tan
Sze Kiat Tan
DEDaniel G. Eichberg
Daniel G. Eichberg
JMJacques J. Morcos
Jacques J. Morcos
Background: Infratentorial pilocytic astrocytomas are uncommon tumors in adulthood but are thought to be prognostically similar to their pediatric counterparts with excellent overall survival following gross total resection. However, given the relative rarity of these tumors, no management guidelines exist for recurrent adult pilocytic astrocytomas (APAs). This lack of consensus is especially problematic for inoperable recurrences or those with aggressive features concerning for malignant transformation.Case Description: In 2017, a 26-year-old female presented with headaches, nausea, vomiting, and blurry vision. A brain magnetic resonance imaging (MRI) demonstrated a large, well-circumscribed mass within the fourth ventricle causing obstructive hydrocephalus. She underwent near-total resection through a midline suboccipital transtonsillar approach. Pathology demonstrated a World Health Organization Grade 1 pilocytic astrocytoma. Despite initial improvement in her symptoms, she developed worsening headaches and lethargy 10 months after surgery and repeat MRI demonstrated recurrent tumor within the entire ventricular system and the subarachnoid spaces of the left cerebellopontine angle suggesting leptomeningeal spread. Due to the unresectable nature of the recurrence, the patient declined any further intervention and succumbed to her disease 6 months later.Conclusion: We present the first case of a recurrent APA presenting with intraventricular and leptomeningeal spread. Although thought to be a benign neoplasm, close interval follow-up with serial imaging is of essential, especially in those patients with known residual tumor, to prevent aggressive recurrences such as this.

22 June 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
SSSauson Soldozy
Sauson Soldozy
DEDaniel G. Eichberg
Daniel G. Eichberg
AMAlexis A. Morell
Alexis A. Morell
ELEvan Luther
Evan Luther
VLVictor M Lu
Victor M Lu
Michael E. IvanMichael E. Ivan
Michael E. Ivan
Brain tumor incidence is on the rise, and glioblastoma comprises the majority of primary tumors. Despite maximal safe resection and adjuvant chemoradiation, median survival for high-grade glioma remains poor. For this reason, it is important to develop and incorporate new treatment strategies. Oncolytic virotherapy has emerged as a viable new therapeutic entity to fill this gap. Preclinical research has shown oncolytic virotherapy to be a robust and effective treatment option for brain tumors, and clinical trials for both adult and pediatric high-grade glioma are underway. The unique and protected environment of the nervous system, in part due to the blood–brain barrier, prevents traditional systemic therapies from achieving adequate penetration. Brain tumors are also heterogenous in nature due to their diverse molecular profiles, further complicating systemic treatment efforts. Oncolytic viruses may serve to fill this gap in brain tumor treatment given their amenability to genetic modification and ability to target unique tumor epitopes. In addition, direct inoculation of the oncolytic virus agent to the tumor bed following surgical resection absolves risk of systemic side effects and ensures adequate delivery. As virotherapy transitions from bench to bedside, it is important to discuss factors to make this transition more seamless. In this article, we describe the current clinical evidence as it pertains to oncolytic virotherapy and the treatment of brain tumors as well as factors to consider for its incorporation into neurosurgical workflow.